In this regard, a recombinant humanized anti‐immunoglobulin E (IgE) antibody (omalizumab), which mainly blocks the binding of IgE to high‐affinity receptors (FceRI) on effector cells and thereby prevents the activation of the IgE‐mediated disease, has been shown safe and effective in the treatment of patients with moderate‐to‐severe allergic asthma,9 refractory chronic spontaneous urticaria,10 AR11, 12 and chronic rhinosinusitis with nasal polyps.13 Here, IGHE is linked to nasal cavity polyp.